Cell-Selective Inhibition of NF-κB Signaling Improves Therapeutic Index in a Melanoma Chemotherapy Model
Article 2011 en
Authors
TE
Thomas Enzler
YS
Yasuyo Sano
MC
Min‐Kyung Choo
Abstract
1 min read
Our findings show that the IκB kinase–NF-κB signaling pathway is important for both promoting treatment resistance and preventing host toxicity in cancer chemotherapy; however, the two functions are exerted by distinct cell type–specific mechanisms and can therefore be selectively targeted to achieve an improved therapeutic outcome.
Kira Bettermann, Mihael Vucur, Johannes Haybaeck, Christiane Koppe, Jörn Janssen, Felix Heymann, Achim Weber, Ralf Weiskirchen, Christian Liedtke, Nikolaus Gaßler, Michael Müller, Rita De Vos, Monika Wolf, Yannick Boege, Gitta Maria Seleznik, Nicolas Zeller, Daniel Erny, Thomas J. Fuchs, Stefan Zoller, Stefano Cairo, Marie‐Annick Buendia, Marco Prinz, Akira Shizuo, Frank Tacke,
Amer A. Beg, Michael Karin, Zarife Sahenk, Micheal Carathers, Michael I. Weinstein, Tepmanas Bupha‐Intr, S. Armando Villalta, Zhiwei Li, Katherine L. Gardner, Nadine Bakkar, Paul M.L. Janssen, Albert S. Baldwin, Denis C. Guttridge, Swarnali Acharyya, Jill A. Rafael‐Fortney, James G. Tidball, Sankar Ghosh
Haroon Khan, Hammad Ullah, Paula C. Castilho, Antonio García‐Ríos, Grazia D’Onofrio, Rosanna Filosa, Fang Wang, Seyed Mohammad Nabavi, Maria Daglia, A. Sanches‐Silva, Kannan R. R. Rengasamy, Juanying Ou, Xiaobo Zou, Jianbo Xiao, Hui Cao
Discussion(0)
No comments yet. Be the first to comment.